US ▾
IEIEX

IDEX (IEX) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Jul 29, 2026

Source: earnings call transcript

Executive summary

IDEX Corporation Q2 FY26 — Strong Orders and Raised Full-Year Outlook

IDEX delivered a strong second quarter, driven by robust organic order growth across all segments, particularly in Health & Science Technologies (HST) due to data center, semiconductor, and space & defense demand. This performance, coupled with outstanding operational execution and expanding backlog, led to a raised full-year 2026 financial outlook. The company is strategically investing in capacity and leveraging its 80/20 framework to capitalize on high-growth opportunities and enhance shareholder value, while also noting early signs of broader industrial demand improvement.

Highlights

5
  • Organic sales grew 5% in Q2 FY26, exceeding expectations.

  • Adjusted EBITDA margin expanded 70 basis points year-over-year to 28.1%.

  • Adjusted EPS grew 12% to $2.32, significantly ahead of guidance.

  • Orders grew 28% organically overall, with HST leading at 47% organic order growth.

  • Record orders of over $1 billion were achieved, driving increased backlog and visibility.

Concerns

3
  • IEEPA tariff refunds reduced organic growth by 2% due to customer rebates.

  • FMT's adjusted EBITDA margin declined 20 basis points year-over-year due to unfavorable mix, despite tariff benefits and productivity.

  • FSDP organic sales declined 1% due to expected reduction in dispensing activity and softer European rescue markets.

Guidance & targets

CategoryTargetConfidence
Full-year 2026 Organic Growth
5% to 6% range
high materiality
High
Full-year 2026 Adjusted EBITDA Margin
27% to 27.3%
high materiality
High
Full-year 2026 Adjusted EPS
$8.70 to $8.85
high materiality
High
Q3 2026 Organic Growth
5% to 7%
medium materiality
High
Q3 2026 Adjusted EBITDA Margin
27% to 27.5%
medium materiality
High
Q3 2026 Adjusted EPS
$2.20 to $2.25
medium materiality
High
Full-year 2026 Capital Expenditures
approximately $110 million
medium materiality
High
Full-year 2026 HST Organic Growth
approximate low double-digit growth
medium materiality
High
Full-year 2026 FMT Organic Growth
slightly up year-over-year
medium materiality
Medium
Full-year 2026 FSDP Organic Growth
slightly up year-over-year
medium materiality
Medium
Quarterly Share Repurchase Pace
around $75 million
medium materiality
High

Segment performance

SegmentRevenueYoYQoQMargin
Health & Science Technologies (HST)
Strong growth driven by semiconductor OE and consumables, data center applications, and Space and Defense. Underlying businesses performed exceptionally well across orders, sales growth, and margin.
Organic orders growth: 47%Adjusted EBITDA margin expansion: 270 bps YoYAdjusted EBITDA margin benefit from tariff refunds: 90 bpsMargin flow-through (ex-tariffs): ~40%Recurring revenues within semicon portfolio: ~50%
—12% organically——
Fluid Metering and Technology (FMT)
Sales growth supported by water platform and mining exposures, offset by softness in ag, chemical, and energy. Unfavorable mix more than offset tariff benefits and productivity, leading to margin decline.
Organic orders growth: 11%Adjusted EBITDA margin benefit from tariff refunds: 180 bps
—1% organically—declined 20 bps YoY
Fire, Safety, & Diversified Products (FSDP)
Orders boosted by strong aerospace demand at BAND-IT and North American fire and integrated system orders. Sales declined due to expected reduction in dispensing activity and softer European rescue markets, partially offset by aerospace strength.
Organic orders growth: 19%Adjusted EBITDA margin benefit from tariff refunds: 120 bps
—-1% organically—decreased 50 bps YoY

Orderbook & backlog

Total Orders over $1 billion Q2 FY26

28% organically YoY

Record orders for the quarter.

HST Backlog for 2027 twice the business set up for the following year Mid-2026

vs. prior year

Provides visibility for 2027 revenue in high-growth areas like data centers.

Risks & headwinds

Softness in ag, chemical, and energy end markets Q2 FY26

Partially offset FMT sales growth to 1% organically.

Mitigation:Management noted industrial order rates showing increasingly encouraging signs.

Expected reduction in dispensing activity and softer European rescue markets Q2 FY26

Contributed to FSDP organic sales decline of 1%.

Mitigation:Partially offset by continued aerospace strength.

Geopolitical uncertainty, interest rate directions, inflation Ongoing

fair amount of uncertainty out there

Mitigation:Not explicitly stated, but company is focused on high-growth areas and operational execution.

What to watch in Q3 FY26

Short-cycle industrial order flow

Q3 FY26
Current starting to show in our businesses
Target Continued broad lift and typical launch of industrial recovery

Why it matters

Indicates broader health of the industrial economy beyond specific high-growth sectors, impacting FMT and FSDP.

As I said, that built as we went through the quarter. It was probably strongest in June, and then it's continued into July. And specifically, I'm referring to the classic kind of up and down the street, small order flow kind of order quantities of 5 to 10 of things, which is a decent part of IDEX business, almost all of which comes through points of distribution.

Find out whether IEX delivers this. Inve re-checks your case every morning.

Q&A highlights

Asked about sequential improvement in traditional short-cycle markets and how the extending lead times in advantaged markets (data center, semicon, space & defense) impact backlog visibility for the next 2-4 quarters.

Eric Ashleman noted that while longer-cycle projects in water and mining initially drove backlog, traditional short-cycle order flow through distribution channels started improving late in Q2 and into July. He highlighted that HST has strong backlog build, with some data center business booked into 2027, giving twice the visibility for the following year compared to last year.

“So it's sort of the midpoint of the year, just as an example, we've kind of got twice the business set up for the following year than we had at this point last year.”

asked by Michael Halloran · answered by Eric Ashleman

3 min read 7 chapters

Detailed narrative

Strong Q2 Performance Driven by High-Growth Platforms

IDEX reported strong Q2 FY26 results with 5% organic sales growth, 28.1% adjusted EBITDA margin (+70 bps YoY), and $2.32 adjusted EPS (+12%). This performance was significantly driven by higher volumes from growth platforms and operational execution, exceeding expectations. Orders grew 28% organically overall, with a record over $1 billion, providing increased confidence and visibility for the remainder of 2026 and into 2027.

Health & Science Technologies (HST) Segment Outperformance

HST led growth with 47% organic order growth and 12% organic revenue growth. This was primarily fueled by strong demand in data center, semiconductor, and space & defense markets, which collectively represent over one-third of HST revenue year-to-date. The segment achieved approximately 40% year-over-year margin flow-through (excluding tariff refunds) and has seen a significant increase in recurring revenues within its semiconductor portfolio to approximately 50% due to Mott's filtration business.

Fluid Metering and Technology (FMT) and Fire, Safety, & Diversified Products (FSDP) Trends

FMT saw 11% organic order growth and 1% organic sales growth, supported by the water platform and mining exposures, partially offset by softness in ag, chemical, and energy. FSDP experienced 19% organic order growth, boosted by strong aerospace demand at BAND-IT and North American fire and integrated system orders, though organic sales declined 1% due to dispensing and European rescue market softness. Both segments showed signs of improving industrial order rates towards the end of Q2.

Impact of IEEPA Tariff Refunds

IEEPA tariff refunds in Q2 FY26 provided a net benefit of $0.08 to adjusted EPS and 130 basis points to adjusted EBITDA margin. However, customer rebates related to these refunds reduced consolidated organic growth by 2% in the quarter. Management clarified that the majority of the tariff refund and associated rebate activity is contained within Q2.

Capital Allocation and Increased Investments

IDEX generated $177 million in free cash flow and maintained over $1.1 billion in liquidity. The company reduced gross leverage to 1.9x from 2.1x a year ago. Capital expenditures guidance for FY26 was raised from $90 million to $110 million to support capacity expansions in high-growth, high-return businesses, primarily within HST, for future growth in 2027 and 2028. Share repurchases totaled $77 million in Q2, with plans to maintain a quarterly pace of around $75 million through 2026, with flexibility for M&A.

Evolving Demand Profile and Backlog Visibility

The company is observing a shift in demand patterns, with longer lead-time orders from advantaged markets (data center, semiconductor, space & defense) providing significant forward visibility, particularly in HST, with some volume already booked into 2027. Simultaneously, more traditional rapid replenishment, short-cycle businesses, especially in FMT, showed encouraging signs of broader lift towards the end of Q2 and into July, suggesting a more typical launch of industrial recovery.

Strategic Focus on Innovation and 80/20

IDEX attributes its success in high-growth markets to intentional investments in acquiring and integrating technologies, particularly through the 80/20 framework. This approach allows the company to develop unique solutions, often at the component level, that address emerging technical needs and leverage existing technologies across different advantaged markets, driving both growth and margin expansion.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.